Cancer cells differ along several dimensions — where they came from, what genetic mistakes they carry, how they look under a microscope, and how they behave. Here's how oncologists sort them.
By tissue of origin (the main classification)
- Carcinoma — the most common (~80–90% of cancers). Starts in epithelial cells that line skin, organs, and glands. Examples: lung, breast, colon, prostate, pancreatic.
- Sarcoma — starts in mesenchymal (connective) tissues: bone, muscle, fat, cartilage, blood vessels.
- Leukemia — cancers of blood-forming cells in the bone marrow, circulating as abnormal white blood cells.
- Lymphoma — cancers of lymphocytes (a type of immune cell), mostly in lymph nodes but can appear anywhere.
- Myeloma — cancer of plasma cells (antibody-making immune cells), primarily in bone marrow.
- CNS tumors — cancers of brain and spinal cord cells (gliomas, meningiomas, etc.). Often classified separately because of the blood-brain barrier.
- Germ cell tumors — from reproductive cells, mostly in ovaries/testes.
- Neuroendocrine tumors — from cells that sit between nerves and hormone-producing cells (e.g., pancreatic NETs, carcinoids).
These categories aren't just labels — they dictate surgery approach, chemotherapy choices, and whether targeted/biologic therapy is even an option.
By the cell type they came from
Within each category, cancer cells are further specified by the normal cell they descend from:
- Adenocarcinoma (glandular epithelium) vs. squamous cell carcinoma (flat surface epithelium) — both are carcinomas but behave and respond differently.
- Osteosarcoma (bone) vs. liposarcoma (fat) vs. leiomyosarcoma (smooth muscle) — all sarcomas, very different diseases.
- B-cell lymphoma vs. T-cell lymphoma — same broad family, completely different treatment regimens.
By molecular/genetic profile (today's most important distinction)
Two breast tumors with identical appearance can be completely different diseases once you test them:
- Driver mutations — the specific genes broken (KRAS, EGFR, BRAF, BRCA1/2, TP53, HER2, ALK, MYC, etc.). Each opens a door to a specific targeted drug.
- Expression patterns — ER+/PR+, HER2+, triple-negative breast cancer; MSI-high vs. MSS in colon cancer; IDH-mutant vs. wild-type glioma.
- Chromosomal changes — translocations like the Philadelphia chromosome (BCR-ABL in CML), or specific fusion genes.
- Tumor microenvironment — how many immune cells have infiltrated ("hot" vs. "cold" tumors), how much fibrosis surrounds the cells, whether new blood vessels are dense.
This is why modern oncology runs genomic and proteomic profiling on tumors — the histology alone no longer directs treatment.
By appearance under the microscope (grade)
- Well-differentiated — cells still look a lot like the parent tissue; often slower-growing.
- Poorly differentiated / anaplastic — cells look wildly abnormal; usually more aggressive.
- Pathologists grade tumors on a scale (G1 well-differentiated to G4 anaplastic), which correlates with aggressiveness.
By behavior (stage and aggressiveness)
- Growth rate — doubling time ranges from days (some leukemias, aggressive lymphomas) to months or years (some prostate, thyroid cancers).
- Metastatic potential — some cancers almost never metastasize (basal cell carcinoma); others do so early (pancreatic, lung).
- Tendency to recur — driven by residual cancer stem cells that resist standard therapy.
- Hormone dependence — prostate and many breast cancers need androgen/estrogen signaling; blocking it can control disease for years.
Why these distinctions matter clinically
- Surgery vs. systemic therapy — a localized sarcoma gets resected; a leukemia is treated with drugs throughout the body.
- Drug selection — HER2+ breast cancer gets trastuzumab; BRAF-mutant melanoma gets BRAF inhibitors; BRCA-mutant ovarian cancer gets PARP inhibitors.
- Prognosis — molecular subtype often predicts outcome better than stage does (e.g., triple-negative breast cancer vs. ER+ disease).
- Clinical trial eligibility — trials increasingly enroll by mutation (any tumor with an NTRK fusion) rather than by organ of origin.
The short version: two tumors in the same organ with the same stage can be very different diseases, and two tumors in different organs with the same mutation are often treated with the same drug. That's the modern, molecular view of cancer — it's less about where and more about what genetic lesion.
(Note: I can give the framework, but I can't diagnose or stage anything specific — that's work for a pathologist with the actual tissue and an oncologist reading the full clinical picture.)